De novo lipogenesis is the biochemical process that turns excess carbohydrate into fatty acids for storage. In Biological Chemistry II, you study it as a regulated metabolic pathway tied to insulin, the liver, and obesity.
De novo lipogenesis is the pathway cells use to make fatty acids from non-lipid starting materials, especially excess glucose and other carbohydrate-derived carbon. In Biological Chemistry II, it shows up as a way the body converts surplus energy into storage form when immediate fuel needs are already met.
The process usually becomes active after a carbohydrate-rich meal, when insulin is high and the body is in a fed state. Glucose is broken down to pyruvate, then carbon skeletons are moved into the mitochondria and reshaped into acetyl-CoA, the basic two-carbon building block for fatty acid synthesis. That acetyl-CoA is not just burned for energy here, it is redirected into making new lipid.
Most fatty acid synthesis happens in the liver, with adipose tissue also contributing. The liver is a major hub because it can package the fatty acids into triglycerides and export them, while adipose tissue can store them locally. This matters in metabolic regulation because the body is deciding whether to use incoming nutrients right away or shift them into long-term storage.
The actual synthesis step uses acetyl-CoA carboxylase and fatty acid synthase, two names that often come up in problem sets and pathway diagrams. Acetyl-CoA carboxylase makes malonyl-CoA, and fatty acid synthase builds the growing fatty acid chain from those units. NADPH supplies the reducing power, so the pathway depends on both carbon flow and cellular reducing capacity.
A useful way to think about de novo lipogenesis is that it is not just fat gain by eating fat. It is fat made from extra carbohydrate. That is why it shows up in discussions of high-sugar diets, insulin signaling, obesity, and insulin resistance. When the pathway is overactive, the liver can accumulate more fat and contribute to metabolic stress instead of simply storing a normal post-meal energy surplus.
De novo lipogenesis shows up in Biological Chemistry II whenever the course shifts from isolated molecules to whole-body metabolic balance. It is a clean example of how hormone signals, enzyme control, and nutrient availability all push metabolism in one direction after a meal.
This term is also a bridge between normal physiology and disease. If you can trace how carbohydrate excess becomes fatty acid, you can explain why diets high in refined sugars are discussed in the same unit as obesity, insulin resistance, and metabolic syndrome. The pathway helps connect a nutrient source to a long-term storage outcome.
It also gives you a concrete way to read pathway diagrams. You can follow the carbon from glucose to acetyl-CoA to malonyl-CoA to fatty acids, then to triglycerides. That chain of steps is the kind of reasoning this course expects when you interpret metabolic maps, compare fed and fasting states, or explain why the liver behaves differently from muscle or adipose tissue.
In obesity-related cases, de novo lipogenesis helps explain why the body can keep making fat even when dietary fat intake is not the whole story. That makes it a useful concept for essays, discussion questions, and problem sets about metabolic disorders.
Keep studying Biological Chemistry II Unit 8
Visual cheatsheet
view galleryInsulin
Insulin is one of the main signals that turns de novo lipogenesis on after a meal. When blood glucose rises, insulin tells cells to store energy and it favors fatty acid synthesis over fuel breakdown. If you are tracing the pathway, insulin is the hormonal cue that makes the fed-state version of metabolism make sense.
Obesity
Obesity is where de novo lipogenesis becomes especially relevant in disease discussion. When the pathway stays active too often or too strongly, extra carbohydrate can be converted into triglycerides and stored. That helps explain how chronic energy surplus feeds into fat accumulation and metabolic dysfunction.
Metabolic Syndrome
Metabolic syndrome groups together problems like insulin resistance, abnormal lipids, and central adiposity, all of which overlap with overactive lipid synthesis. De novo lipogenesis helps explain why the liver can contribute to higher triglycerides and worse metabolic control in this condition.
adipokines
Adipokines connect fat tissue to the rest of the body through signaling molecules. In obesity, changes in adipokine signaling can affect insulin sensitivity and inflammation, which then feeds back into how strongly pathways like de novo lipogenesis are regulated. This is one reason fat tissue is treated like an endocrine organ in the course.
A quiz or problem-set question may ask you to trace what happens to excess glucose after a high-carbohydrate meal, and de novo lipogenesis is the pathway you would name. You might also get a diagram and need to identify the fed-state pathway that converts acetyl-CoA into fatty acids in the liver. In case-based questions, the move is to connect high insulin, energy surplus, and triglyceride storage to the buildup of fat in obesity or insulin resistance. If the prompt asks why the liver accumulates lipid, you should point to the conversion of carbohydrate carbon into fatty acids rather than just saying, "fat is stored."
These are opposites in metabolism. De novo lipogenesis builds fatty acids from acetyl-CoA and uses energy, while beta-oxidation breaks fatty acids down to produce acetyl-CoA and release energy. If a question is about the fed state and storage, think lipogenesis. If it is about fasting or fuel release, think beta-oxidation.
De novo lipogenesis is the synthesis of fatty acids from non-lipid precursors, especially excess carbohydrate.
In Biological Chemistry II, the pathway is tied to the fed state, insulin signaling, and energy storage.
The liver is a major site of this process, and the fatty acids made there can be turned into triglycerides.
Acetyl-CoA carboxylase and fatty acid synthase are central enzymes you should recognize in pathway diagrams.
When de novo lipogenesis is too active, it can contribute to obesity, insulin resistance, and metabolic disease.
It is the metabolic process that makes fatty acids from non-lipid sources like excess glucose. In the course, you usually see it as a fed-state pathway controlled by insulin and linked to storage in the liver and adipose tissue.
Yes, that is the basic idea. The body can convert extra carbohydrate into fatty acids, then package those fatty acids into triglycerides for storage. That is why it comes up in obesity and high-sugar diet discussions.
It happens mainly in the liver, with adipose tissue also contributing. The liver is especially important because it can make fatty acids and send them onward for triglyceride storage or transport.
De novo lipogenesis builds fatty acids, while beta-oxidation breaks them down. The first uses energy and happens more in the fed state, while the second releases energy and is more active when the body needs fuel.